Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: Peptide vaccination results in selective expansion of Th1-like counterparts

Cancer Research

Volumn 69, Issue 20, 2009, Pages 8085-8093

  Jandus, Camilla ^a   Bioley, Gilles ^a,b   Dojcinovic, Danijel ^d   Derré, Laurent ^a   Baitsch, Lukas ^a   Wieckowski, Sébastien ^b   Rufer, Nathalie ^b   Kwok, William W ^e   Tiercy, Jean Marie ^f   Luescher, Immanuel F ^d   Speiser, Daniel E ^a,c   Romero, Pedro ^a,c  

^a Hopital Orthopedique de la Suisse Romande   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c National Center of Competence in Research in Molecular Oncology   (Switzerland)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^e BENAROYA RESEARCH INSTITUTE   (United States)

^f UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DQ ANTIGEN; HLA DQ6 ANTIGEN; MELAN A VACCINE; PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL LABELING; CELL PROLIFERATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; IN VITRO STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH1 CELL; TUMOR IMMUNITY; VACCINATION;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HLA-A2 ANTIGEN; HLA-DQ ANTIGENS; HUMANS; IMMUNOTHERAPY; MALE; MART-1 ANTIGEN; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; TH1 CELLS; VACCINATION;

EID: 70350127838     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2226     Document Type: Article

References (50)

1. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008;8:351-360
2. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308.
3. Mahnke YD, Speiser D, Luescher IF, Cerottini JC, Romero P. Recent advances in tumour antigen-specific therapy: in vivo veritas. Int J Cancer 2005;113:173-178 (Pubitemid 39628306)
4. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647 (Pubitemid 21917508)
5. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004;350:1461-1463
6. Parmiani G, Castelli C, Santinami M, Rivoltini L. Melanoma immunology: past, present and future. Curr Opin Oncol 2007;19:121-127 (Pubitemid 46204351)
7. Hofbauer GF, Kamarashev J, Geertsen R, Boni R, Dummer R. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and meta-static melanoma: frequency and distribution. Melanoma Res 1998;8:337-343 (Pubitemid 28442565)
8. Castelli C, Storkus WJ, Maeurer MJ, et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995;181:363-368
9. Benlalam H, Linard B, Guilloux Y, et al. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol 2003;171:6283-6289 (Pubitemid 37467252)
10. Romero P, Gervois N, Schneider J, et al. Cytolytic T lymphocyte recognition of the immunodominant HLAA* 0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 1997;159:2366-2374 (Pubitemid 127681029)
11. Schneider J, Brichard V, Boon T, Meyer zum Buschenfelde KH, Wolfel T. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int J Cancer 1998;75:451-458 (Pubitemid 28100050)
12. Bioley G, Jandus C, Tuyaerts S, et al. Melan-A/MART- 1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol 2006;177: 6769-6779 (Pubitemid 44715041)
13. Valmori D, Levy F, Godefroy E, et al. Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen. Clin Immunol 2007;122:163-172 (Pubitemid 46084923)
14. Jackson H, Dimopoulos N, Mifsud NA, et al. Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NYESO- 1. J Immunol 2006;176:5908-5917
15. Surman S, Lockey TD, Slobod KS, et al. Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc Natl Acad Sci U S A 2001;98: 4587-4592 (Pubitemid 32295020)
16. Kim SK, DeMars R. Epitope clusters in the major outer membrane protein of Chlamydia trachomatis. Curr Opin Immunol 2001;13:429-436 (Pubitemid 32728475)
17. Valmori D, Fonteneau JF, Lizana CM, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998;160:1750-1758 (Pubitemid 28110836)
18. Lienard D, Rimoldi D, Marchand M, et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun 2004;4:4. (Pubitemid 40217418)
19. Ayyoub M, Zippelius A, Pittet MJ, et al. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin Cancer Res 2003;9:669-677 (Pubitemid 36182599)
20. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115:739-746 (Pubitemid 40322250)
21. Pittet MJ, Valmori D, Dunbar PR, et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999;190:705-715 (Pubitemid 29428652)
22. Romero P, Dunbar PR, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:1641-1650 (Pubitemid 28516109)
23. Rufer N, Reichenbach P, Romero P. Methods for the ex vivo characterization of human CD8+ T subsets based on gene expression and replicative history analysis. Methods Mol Med 2005;109:265-284
24. Rufer N, Zippelius A, Batard P, et al. Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood 2003;102:1779-1787 (Pubitemid 37022574)
25. Dumont-Girard F, Roux E, van Lier RA, et al. Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood 1998;92:4464-4471 (Pubitemid 28544365)
26. Ahmadzadeh M, Felipe-Silva A, Heemskerk B, et al. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 2008;112:4953-4960
27. Kryczek I, Liu R, Wang G, et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009;69:3995-4000.
28. Lemaitre F, Viguier M, Cho MS, et al. Detection of low-frequency human antigen-specific CD4(+) T cells using MHC class II multimer bead sorting and immuno-scope analysis. Eur J Immunol 2004;34:2941-2949 (Pubitemid 39430169)
29. Wong R, Lau R, Chang J, et al. Immune responses to a class II helper peptide epitope in patients with stage III/ IV resected melanoma. Clin Cancer Res 2004;10:5004-5013 (Pubitemid 39099774)
30. Zhang Y, Renkvist N, Sun Z, et al. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. Eur J Immunol 2005;35:1066-1075 (Pubitemid 40542213)
31. Danke NA, Koelle DM, Yee C, Beheray S, Kwok WW. Autoreactive T cells in healthy individuals. J Immunol 2004;172:5967-5972
32. Voelter V, Rufer N, Reynard S, et al. Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor. Int Immunol 2008;20:1087-1096
33. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. NatMed 2004;10:942-949 (Pubitemid 39273735)
34. Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother 2006;55:1185-1197 (Pubitemid 43992045)
35. Jandus C, Bioley G, Speiser DE, Romero P. Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol Immun-other 2008;57:1795-1805
36. Nishikawa H, Jager E, Ritter G, Old LJ, Gnjatic S. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 2005;106:1008-1011
37. van der Burg SH, Piersma SJ, de Jong A, et al. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A 2007;104:12087-12092
38. Vence L, Palucka AK, Fay JW, et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2007; 104:20884-20889
39. Wang HY, Lee DA, Peng G, et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004;20:107-118 (Pubitemid 38134298)
40. Wang HY, Peng G, Guo Z, Shevach EM, Wang RF. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol 2005;174:2661-2670 (Pubitemid 40279680)
41. Phan GQ, Touloukian CE, Yang JC, et al. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 2003;26:349-356
42. Valmori D, Souleimanian NE, Tosello V, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A 2007;104:8947-8952 (Pubitemid 47175417)
43. Nishikawa H, Tsuji T, Jager E, et al. Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood 2008;111:1404-1412 (Pubitemid 351213427)
44. Hueman MT, Stojadinovic A, Storrer CE, et al. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine. Breast Cancer Res Treat 2006;98:17-29. (Pubitemid 44050777)
45. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006;107:628-636 (Pubitemid 43076387)
46. Zhou G, Levitsky HI. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 2007;178: 2155-2162 (Pubitemid 46233413)
47. Nishikawa H, Kato T, Tawara I, et al. IFN-γ controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. J Immunol 2005; 175:4433-4440 (Pubitemid 41361979)
48. Glisic S, Klinker M, Waukau J, et al. Genetic association of HLA DQB1 with CD4+CD25+(high) T-cell apoptosis in type 1 diabetes. Genes Immun 2009;10:334-340
49. Derre L, Bruyninx M, Baumgaertner P, et al. In vivo persistence of codominant human CD8+ T cell clono-types is not limited by replicative senescence or functional alteration. J Immunol 2007;179:2368-2379
50. Speiser DE, Baumgaertner P, Barbey C, et al. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol 2006;177:1338-1348 (Pubitemid 44036641)